Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Posts 102 Percent Jump in 2016 Revenues

NEW YORK (GenomeWeb) – Epigenomics today reported a 102 percent increase in 2016 revenues on strong sales of its Epi proColon blood-based colorectal cancer screening test.

For the 12-month period ended Dec. 31, Epigenomics' revenues climbed to €4.2 million ($4.6 million) from €2.1 million the year before. Product revenues were up 41 percent year-over-year to €2.2 million from €1.6 million, while licensing revenues increased to €600,000 from €200,000. The company also generated revenues of €1.4 million through the sale of intellectual property rights.

Epi proColon received US Food and Drug Administration approval in April 2016.

Epigenomics' net loss for the year widened to €11.2 million, or €.55 per share, from €9.0 million, or €.52 per share, in 2015. The company attributed the modest widening of  loss per share to a greater average number of shares outstanding in 2016 versus 2015.

The company's 2016 R&D spending decreased 12 percent to €5.1 million from €5.8 million, while its SG&A costs doubled to €10.2 million from €5.1 million, primarily due to share-based payment expenses and legal and audit fees for a filing with the US Securities and Exchange Commission.

Epigenomics finished 2016 with €11.5 million in cash and cash equivalents, and €753,000 in marketable securities.

Looking ahead, the firm said it expects its 2017 revenues to be "broadly consistent" with 2016 revenues, noting that its revenues can vary substantially based upon timing of decisions on medical guidelines and payor coverage related to Epi proColon. It also said that its current cash resources are expected to be sufficient to fund operations beyond 2017.

Separately today, Epigenomics announced that it has accepted a takeover offer by Blitz F16-83, a subsidiary of Chinese private equity firm Cathay Fortune International.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.